argenx SE's revenue for the
three
months ended in Dec. 2024 was MXN15,400 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2024 was MXN42,093 Mil.
argenx SE's Revenue per Share for the
three
months ended in Dec. 2024 was MXN231.22.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was MXN662.15.
During the past 12 months, the average Revenue per Share Growth Rate of argenx SE was 63.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 55.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 98.20% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 52.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, argenx SE's highest 3-Year average Revenue per Share Growth Rate was 197.50% per year. The lowest was -20.70% per year. And the median was 57.40% per year.
argenx SE Revenue Historical Data
The historical data trend for argenx SE's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, argenx SE's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
argenx SE's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, argenx SE's Revenue distribution charts can be found below:
* The bar in red indicates where argenx SE's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN42,093 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
argenx SE (MEX:ARGX) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
argenx SE Revenue Related Terms
Thank you for viewing the detailed overview of argenx SE's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MEX:ARGX has been successfully added to your 